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Patients with iatrogenic Creutzfeldt-Jakob disease due to administration of cadaver-sourced growth hormone during childhood are
still being seen in the UK 30 years after cessation of this treatment. Of the 77 patients who have developed iatrogenic Creutzfeldt-
Jakob disease, 56 have been genotyped. There has been a marked change in genotype proﬁle at polymorphic codon 129 of the
prion protein gene (PRNP) from predominantly valine homozygous to a mixed picture of methionine homozygous and methionine-
valine heterozygous over time. The incubation period of iatrogenic Creutzfeldt-Jakob disease is signiﬁcantly different between all
three genotypes. This experience is a striking contrast with that in France and the USA, which may relate to contamination of
different growth hormone batches with different strains of human prions. We describe the clinical, imaging, molecular and autopsy
features in 22 of 24 patients who have developed iatrogenic Creutzfeldt-Jakob disease in the UK since 2003. Mean age at onset of
symptoms was 42.7 years. Gait ataxia and lower limb dysaesthesiae were the most frequent presenting symptoms. All had cere-
bellar signs, and the majority had myoclonus and lower limb pyramidal signs, with relatively preserved cognitive function, when
ﬁrst seen. There was a progressive decline in neurological and cognitive function leading to death after 5–32 (mean 14) months.
Despite incubation periods approaching 40 years, the clinical duration in methionine homozygote patients appeared to be shorter
than that seen in heterozygote patients. MRI showed restricted diffusion in the basal ganglia, thalamus, hippocampus, frontal and
the paracentral motor cortex and cerebellar vermis. The electroencephalogram was abnormal in 15 patients and cerebrospinal ﬂuid
14-3-3 protein was positive in half the patients. Neuropathological examination was conducted in nine patients. All but one
showed synaptic prion deposition with numerous kuru type plaques in the basal ganglia, anterior frontal and parietal cortex,
thalamus, basal ganglia and cerebellum. The patient with the shortest clinical duration had an atypical synaptic deposition of
abnormal prion protein and no kuru plaques. Taken together, these data provide a remarkable example of the interplay between
the strain of the pathogen and host prion protein genotype. Based on extensive modelling of human prion transmission barriers in
transgenic mice expressing human prion protein on a mouse prion protein null background, the temporal distribution of codon
129 genotypes within the cohort of patients with iatrogenic Creutzfeldt-Jakob disease in the UK suggests that there was a point
source of infecting prion contamination of growth hormone derived from a patient with Creutzfeldt-Jakob disease expressing prion
protein valine 129.
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Introduction
Prion diseases are neurodegenerative conditions of humans
and animals caused by the templated misfolding and aggre-
gation of cellular prion protein (Collinge, 2001). It is
becoming increasingly clear that the more common degen-
erative brain diseases, such as Alzheimer’s and Parkinson’s
disease, involve the accumulation of aggregates of mis-
folded host proteins by a process of seeded protein poly-
merization (Jucker and Walker, 2013). In this way, prion
diseases can be considered a paradigm for the other protein
misfolding diseases and prion-like mechanisms are now one
of the most rapidly developing research areas in neurode-
generation research internationally. The remarkable and
apparently unique phenomenon of zoonotic and horizontal
transmission of prions, affords special opportunities to
understand the host determinants of clinical phenotype, in-
fection and susceptibility. Genetic variation in the prion
protein gene (PRNP), speciﬁcally a common polymorphism
at codon 129 encoding either methionine or valine, is a key
risk factor and determinant of susceptibility, clinical pheno-
type and incubation time (Collinge et al., 1991, 2006;
Palmer et al., 1991; Pocchiari et al., 2004; Mead et al.,
2006, 2009a).
Treatment of persons of short stature with cadaver-
sourced growth hormone was ﬁrst given in 1958 and
1 year later in the UK as a clinical trial (Raben, 1958). In
1985, four cases of Creutzfeldt-Jakob disease (CJD) were
reported in patients who had received cadaver-sourced
growth hormone in the UK (Powell Jackson et al., 1985).
Further cases were reported from the USA, Europe and
Australia and treatment with human growth hormone was
stopped in the UK in May 1985 by which time recombinant
growth hormone was becoming available. Of 1849 persons
who received growth hormone in the UK between 1959 and
1985, 38 were known to have developed CJD by 2000 and
the estimated risk of developing iatrogenic CJD was at that
time 4.5%, this risk being greatest in those patients who
received treatment at ages 8–10 years with a peak incubation
period of 20 years (Swerdlow et al., 2003). One preparation
(Hartree modiﬁed Wilhelmi preparation) was common to all
patients who developed iatrogenic CJD.
The Medical Research Council (MRC) Prion Unit/
National Prion Clinic enrolled two patients with iatrogenic
growth hormone related CJD into a clinical trial of quina-
crine (PRION-1) (Collinge et al., 2009) between 2002 and
2006 and four others were seen by the Unit over that
period. Subsequently the National Prion Monitoring
Cohort study (Thompson et al., 2013) was established
and between October 2008 and present day (2015) has
reviewed nearly all cases of prion disease in the UK includ-
ing cases of iatrogenic CJD. All cases of iatrogenic CJD
were followed up with frequent neurological assessment
until death and autopsy conﬁrmation of the diagnosis
was made in the majority. This paper reports the clinical
and neuropsychological ﬁndings, prion protein gene ana-
lysis, MRI, EEG, CSF and pathological ﬁndings in these
cases seen between 2003 and 2014. In light of surprising
genetic ﬁndings in recent cases we combined our data with
those available on older cases for a complete study of the
UK experience of cadaveric pituitary growth hormone-
related CJD.
Materials and methods
Study design
A national referral system for prion diseases was set up in the
UK in 2004. UK neurologists were asked by the Chief Medical
Ofﬁcer to refer all patients with suspected prion disease jointly
to the National CJD Research and Surveillance Unit
(Edinburgh, UK) and to the NHS National Prion Clinic
(London, UK). This enables epidemiological surveillance, pro-
vision of specialist clinical care and also participation in clin-
ical research and the National Prion Monitoring Cohort study;
recruitment of patients to this study began in 2008. All but 2
of 18 patients with CJD in this study who had received ca-
daver-derived growth hormone were recruited into the Cohort
study. In addition, similar patients seen by clinicians in the
MRC Prion Unit/NPC as part of the PRION-1 trial of quina-
crine (Collinge et al., 2009), between 2001 and 2007, were
included in the current study.
After the initial visit, repeated follow-up visits were made to
assess progress of the disorder at 6-week intervals until
death. Progression was assessed by the MRC Prion Disease
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Rating Scale (MRC Scale), systematic neurological and neuro-
psychological assessments, and a range of other rating scales
(Thompson et al., 2013). Ethical approval for these studies
was obtained from the Local Research Ethics Committee of
UCL Institute of Neurology/National Hospital for Neurology
and Neurosurgery.
Magnetic resonance imaging
MRI studies performed at either 1.5 or 3T were reviewed in
20 of the patients. In six of the MRI studies, diffusion
weighted images (DWI) were not available and cortical in-
volvement could not be assessed in a comparable way. The
images were reviewed by a consultant neuro-radiologist and
a consultant neurologist, both with 9 years’ experience in
prion disease imaging, and agreement was achieved via con-
sensus review. Signal abnormality was assessed in the caudate,
putamen and thalamus on T2-weighted, ﬂuid attenuation in-
version recovery (FLAIR) and/or DWI sequences. Cortical
signal abnormality was assessed on DWI sequences where
available in the following areas: frontal, parietal, temporal,
occipital, cingulate, insula, hippocampus and cerebellum. Any
other relevant ﬁndings were also noted.
Neuropathology
Autopsies were performed either at the local hospital or the
National Hospital for Neurology and Neurosurgery. Autopsies
were carried out in a post-mortem room designated for high
risk autopsies. Informed consent to use the tissue for research
was obtained in all cases. The anterior frontal, temporal, par-
ietal and occipital cortex and the cerebellum (at the level of
dentate nucleus) were dissected during the post-mortem pro-
cedure. The remaining tissue was stored permanently in 10%
formalin to allow for additional tissue sampling. In cases
where retention of the entire brain was not consented, add-
itional tissue sampling of posterior frontal cortex including
motor strip, basal ganglia, thalamus, hippocampus and cere-
bellar vermis was carried out during post-mortem dissection.
Tissue samples were immersed in 10% buffered formalin and
prion infectivity was inactivated by immersion into 98%
formic acid for 1 h. Tissue samples were processed to parafﬁn
wax and tissue sections were routinely stained with haema-
toxylin and eosin and immunostained for abnormal prion pro-
tein [anti-PrP monoclonal antibody ICSM35 (D-Gen Ltd);
0.1 mg/ml solution] according to published protocols
(Wadsworth et al., 2008c). The extent of neuropil vacuolation
and pattern and intensity of prion protein deposition was as-
sessed semiquantitatively.
Molecular strain typing of
disease-related PrP
Frozen brain tissue was available from seven patients for dis-
ease-related prion protein (PrPSc) molecular strain typing
(Collinge et al., 1996; Hill et al., 2003). Biochemical studies
were carried out in a microbiological containment level 3 fa-
cility with strict adherence to safety protocols. Ten per cent
(w/v) brain homogenates (grey matter; frontal cortex) were
prepared in Dulbecco’s phosphate-buffered saline lacking
Ca2+ or Mg2+ ions using tissue grinders (Wadsworth et al.,
2008c). Proteinase K digestion (50 mg/ml ﬁnal protease concen-
tration, 1 h, 37C), electrophoresis [on 16% Tris-glycine gels
(Invitrogen)] and immunoblotting using anti-PrP monoclonal
antibody 3F4 (Cambridge Bioscience) was performed as
described previously (Wadsworth et al., 2001, 2008c; Hill
et al., 2003). Internal typing controls of deﬁned PrPSc types
were analysed on each gel when assigning PrPSc type to an
unknown sample. Different human PrPSc isoforms, referred
to as molecular strain types, can be identiﬁed in the brain of
patients with phenotypically distinct forms of CJD and are
classiﬁed by both the fragment size and ratio of the three prin-
cipal PrP bands seen after protease digestion. To date we have
characterized four major types of human PrPSc that can be
commonly identiﬁed in sporadic and acquired human prion
diseases (Collinge et al., 1996; Collinge, 2001; Hill et al.,
2003; Wadsworth et al., 2003, 2008a, b), although much
greater heterogeneity seems likely (Hill et al., 2003;
Wadsworth and Collinge, 2011). Sporadic and iatrogenic
CJD (classical CJD) and kuru are associated with PrPSc types
1–3, whereas type 4 PrPSc is uniquely associated with variant
CJD. An earlier classiﬁcation of PrPSc types seen in classical
CJD described only two banding patterns (Parchi et al., 1996,
1999) with PrPSc types 1 and 2 that we describe corresponding
with the type 1 pattern of Gambetti and Parchi and colleagues,
and our type 3 fragment size corresponding to their type 2
pattern. More recently Parchi et al. (2011) have demonstrated
that their PrPSc types 1 and 2 can be further classiﬁed by mo-
lecular criteria and have integrated these data with clinical-
pathological variations that are seen in patients with classical
CJD. Currently the number of distinct prion strains that com-
prise classical CJD remains unknown and a uniﬁed interna-
tionally accepted classiﬁcation system of PrPSc subtypes
remains an important goal (Brandner, 2011).
Genetic analyses
In addition to the detailed analysis of the clinical data in the
22 patients, which is the main focus of this paper, data were
retrieved from the UK iatrogenic CJD database, principally to
determine the genotypes in all cases of the polymorphism at
codon 129 in the PRNP gene. The database contains details of
growth hormone preparations received by the patients and
duration of disease assessed by the local clinician.
Polymorphism at codon 129 was determined in 50 of 77 pa-
tients by the MRC Prion Unit or obtained from a previous
publication (Swerdlow et al., 2003); another six were assessed
by other laboratories. Twenty-one patients did not have gene
sequencing or screening for PRNP codon 129 polymorphism.
Whole exome sequencing was done using the Agilent
SureSelect Human All Exon v2 target enrichment kit.
Sequencing was performed on an Illumina HiSeq2000 and
achieved an average 30-fold depth-of-coverage of target
sequence.
Results
Details of the individual patient data are shown in
Supplementary Table 1. The following is a summary of
these data.
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Patients
Twenty-two patients (ﬁve female) aged 27–51 (mean 42.8)
years were studied sequentially from 2003. All have died.
Average follow-up period until death was 7.3 months and
the maximum follow-up period was 24.9 months. In a
subset of patients, progression was assessed by serial meas-
urements of the MRC Prion Disease Rating Scale (MRC
Scale) (Fig. 1). There were between two and 15 follow-up
assessments for each patient (average of 6.7 per person);
three were assessed twice, one three times, one four times,
two ﬁve times, one six times and three seven times, one
nine times, two 10 times and one 15 times. The mean
and median duration of illness was 16.0 (4–32) months
and 14.0 months, respectively.
The precise dates of starting and stopping treatment with
any type of growth hormone were known for all but one
patient; details of treatment with one product (Hartree
modiﬁed Wilhelmi preparation), which is most implicated
as the causative agent of iatrogenic CJD in the UK, were
incomplete in two patients. The range of minimum possible
incubation times, calculated as the time from last injection
of any type of growth hormone to onset of symptoms was
18.3–33.6 (mean 25.9) years and the range of maximum
incubation periods calculated from time of ﬁrst injection to
onset of symptoms was 23.2–43.3 (mean 32.8) years,
assuming the infection occurred at the ﬁrst or last exposure.
The range of incubation times from midpoint of treatment,
ignoring missed injections, with any type of growth hor-
mone to onset of symptoms was 20.6–37.6 (mean 29.3)
years. Similar calculations were done for the Hartree
modiﬁed Wilhelmi preparation product, the only prepar-
ation received by every patient, and the most probable
source of infection. The range of minimum incubation per-
iods was 22.1–32.8 (mean 27.9) years, maximum incuba-
tion period was 22.6–39.8 (mean 31.3) years and the range
of incubation periods from the midpoint of injections was
22.5–35.8 (mean 29.9) years. The average and median age
at treatment with growth hormone was 9.3 (2–16) years
and 9.0 years. The cumulative dose of growth hormone
given to each patient is not available but the total duration
of treatment is known and has been used as a surrogate
measure of total exposure (Supplementary Table 1). There
was no relation between duration of dosage of any product
and incubation period (r = 0.102, P = 0.53 for Hartree
modiﬁed Wilhelmi preparation; r = 0.08, P = 0.61 for all
preparations).
Symptoms
Initial symptoms are summarized in Table 1. Ataxia of gait
was the ﬁrst symptom in 11 of 22 patients and nearly all
developed this symptom within the ﬁrst 2 months. Other
initial symptoms were tremor, leg pain, daytime somno-
lence, dizziness, headaches, myoclonus and cognitive im-
pairment. There were two patients who described
unsteadiness induced by a moving stimulus such as
waves; one could not stand in the sea due to poor balance
and another became unsteady when getting out of shallow
water.
During the evolution of the disease all patients ultimately
had unsteadiness of gait and other cerebellar symptoms
such as limb dysmetria (lower limb more so than upper
limb). Thirteen patients described pain in the lower limbs,
including hypersensitivity to light touch in the legs and a
variety of dysaesthesiae such as an ‘itchy sensation’, numb-
ness, patchy tingling and burning in the lower limbs. Two
had hip pain, three had knee pain, one had both and one
patient had calf pain. Ten patients had a sleep disturbance,
including daytime somnolence, insomnia and early waking.
Two of these patients had excessive sleepiness during the
day, falling asleep in public places. There was no pattern of
these symptoms occurring at any particular stage through-
out the course of the illness.
Neurological signs
The neurological ﬁndings when ﬁrst seen in the National
Prion Clinic are summarized in Table 1. All patients had
ataxia of gait, a lesser ataxia of the limbs and most
had myoclonus. Half had a cerebellar dysarthria.
Seventeen had evidence of pyramidal lesions with either
brisk reﬂexes or extensor plantar responses. Eleven had
reduced power in lower limbs.
Relative to the marked ataxia, cognition was initially less
affected in most patients. Nineteen patients had a Mini-
Mental State Examination assessed at the ﬁrst visit. Fifteen
of these patients scored 518/30 (mean 23.7 range 18–29/30),
Figure 1 Clinical progression assessed on the MRC Prion
Disease Rating Scale. Broken line connects time of first symptom
to the first assessment on the MRC scale assuming patient would
have scored 20 before disease onset. Continuous lines join con-
secutive assessments indicated by dots. Last assessment is the point
at which the patient first scored 0 on the rating scale; death
occurred shortly after this in all cases. Horizontal axis = time in
months from onset of disease; vertical axis = MRC Prion Rating
Scale score; red lines = codon 129 MM patients; blue = codon 129
MV patients.
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losing points on orientation and recall. One patient could not
be tested adequately as she had a history of stable long term
cognitive problems. Of the other six patients three were too
impaired to test and three scored 8, 7 and 4/30, respectively.
There was no correlation between when cognitive function
was ﬁrst assessed and the duration of symptoms. To delineate
further the earliest cognitive deﬁcits a short cognitive exam-
ination, speciﬁcally designed for patients with prion disease,
was done in the nine patients well enough to cooperate.
Executive function assessed by letter ﬂuency (1 min) was
mildly impaired in all when ﬁrst tested 3–19 (mean 8.4)
months after the ﬁrst symptoms. Verbal or visual recognition
memory was mildly impaired in the three patients seen more
than 1 year after onset of symptoms. All had preserved visual
perception. Four patients had more extensive psychometric
testing conﬁrming mild memory impairment in all and
mildly impaired executive function in three. Subsequently
there was progressive decline in cognitive function; increasing
dysarthria limited assessment later in the course of the disease.
Over a period of months the ataxia increased resulting in
loss of ambulation and inability to groom, dress and feed
without assistance. Leg weakness increased and contributed
to the loss of ambulation. The dysarthria progressively
increased and speech became unintelligible. Speech output
then gradually declined making cognitive assessment difﬁ-
cult. Myoclonus usually persisted but the pain in the limbs
lessened in most patients. Incontinence of urine and faeces
developed in all. Ultimately the patient entered an akinetic
mute state.
Magnetic resonance imaging
MRI brain scans were available in 20 patients (ﬁve female)
mean age 42.7 years (range 27–51 years). Eighteen of the
patients scanned showed caudate, putamen and thalamic
signal abnormality (Fig. 2 and Table 2). The thalamic
signal abnormality was seen in all the patients where
there was basal ganglia signal abnormality and was
mostly diffuse with clear involvement of all the thalamic
nuclei. Of the cortical areas, the cingulate gyrus most com-
monly showed signal abnormality (15 of 17 patients who
underwent DWI). The frontal cortex was next most com-
monly involved (14 of 17 patients), with focal involvement
of the medial aspect of the precentral gyrus and paracentral
lobule bilaterally seen in 10 of 16 (Fig. 2) with relative
sparing of the postcentral gyrus. In ﬁve of these patients,
the abnormality was conﬁned to the precentral gyrus. The
next most commonly affected cortical area was the superior
cerebellar vermis, seen in 7 of 16 patients (Fig. 3). The
parietal, temporal and insula cortices were rarely involved
and the occipital cortex was not involved in any of the
cases (Table 2). Involvement of the hippocampus, particu-
larly the tail, was seen in nine patients. Additional MRI
ﬁndings included one patient with septo-optic dysplasia
and partial agenesis of the corpus callosum.
Prion protein gene sequencing
All patients were analysed for the entire PRNP open read-
ing frame by Sanger sequencing. None had a mutation.
Table 1 Summary of initial symptoms and neurological signs when first seen
Initial symptoms Clinical signs
Case First Second Gait
ataxia
Limb
ataxia
Pyramidal Leg
weakness
Myoclonus Dysarthria Sensory
signs
1 Tremor hands Unsteady + + + + + + -
2 Tremor hands Unsteady + + - - - - -
3 Tremor/unsteady Memory decline + + + + + - +
4 Unsteady Myoclonus + + + + + + -
5 Unsteady Memory decline + + + + + + -
6 Unsteady Tremor hands + + - - + - +
7 Myoclonus Tremor hands + + + + + + +
8 Tremor hands Unsteady + + + - + - -
9 Unsteady Somnolence + + + - + + -
10 Somnolence Limb pain + + + - + - +
11 Unsteady Limb pain + + + + + - +
12 Unsteady Myoclonus + + + - + - +
13 Limb pain Behaviour/unsteady + + + + + + +
14 Limb pain Behaviour/unsteady + + + + + + +
15 Unsteady Myoclonus + + + + + + -
16 Behaviour/memory Unsteady + + + - + - -
17 Unsteady Behaviour + + + + - + -
18 Dizzy Unsteady + + + - + + +
19 Tremor Unsteady + + - - + + -
20 Unsteady Memory decline + + + + + - +
21 Tremor/unsteady Limb pain + + + - + + +
22 Limb pain Behaviour/unsteady + + + + - - +
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At polymorphic codon 129 there were 17 heterozygotes
(MV), four methionine homozygotes (MM) and one
valine homozygote (VV).
Although there were insufﬁcient data to compare statis-
tically survival times by 129 polymorphism, MM patients
had a mean duration of 7.8 months, the VV patient 17
months and those with the MV polymorphism a mean of
18.6 months (10–32 months). In addition, the duration of
disease from ﬁrst symptom was signiﬁcantly longer in the
heterozygotes (P5 0.02 two-tailed t-test). Although there
were only four patients who were MM three of these
had the most rapid progression (P = 0.04, Mann Whitney
U-test).
The average incubation time from the midpoint of
growth hormone administration was 28.6 years for MV
and 31.8 years for MM (four patients). The patient who
carried the VV polymorphism developed symptoms after
20.6 years.
Combining the data with those already published (cases
up to 2000) there were 33 heterozygotes (MV), and 23
homozygotes, 15 of whom were VV and eight MM.
There was a highly signiﬁcant difference in the distribution
of the three polymorphisms at codon 129 over time and
incubation period, with each pairwise comparison of geno-
types being statistically signiﬁcant in post hoc analyses
[MM mean 30.8 years (95% conﬁdence interval
26.9–32.6), MV mean 23.4 years (9.0–36.7), VV mean
14.3 years (7.7–20.2), ANOVA P5 107]. Fourteen of
15 valine homozygotes occurred before 1998 and seven
of eight methionine homozygotes occurred after 2004
(Fig 4).
Whole exome sequencing
Twenty-seven iatrogenic CJD cases, including the 22 in this
report and one from outside the UK, were exome
sequenced and allele frequencies compared with internal
and publicly available control frequencies. The top-ranked
single variant association was in RRP9 (ribosomal RNA
processing 9 small subunit gene), for which association
testing of rs145537768, p.R143W, achieved P = 107,
Fisher’s exact test. While this was the strongest statistical
association in the exome study it does not surpass standard
statistical thresholds for a genome-wide ﬁnding
(P5 5  108) and requires replication study in other na-
tional cohorts of iatrogenic CJD to be recognized as a con-
ﬁrmed association. The variant was detected in ﬁve growth
hormone-related iatrogenic CJD cases (n = 27), conﬁrmed
in all cases by Sanger sequencing, but was not found in
574 internal non-prion disease controls. This variant
Figure 2 MRI findings in a 46-year-old male patient with iatrogenic CJD due to growth hormone. Basal ganglia and thalamic
hyperintensity is seen on T2-weighted images (A), DWI at b = 1000s/mm
2 (B) and (C) DWI at b = 3000s/mm2. Cortical hyperintensity in the
paracentral lobule bilaterally and right precentral gyrus is not visualized on T2-weighted images (D) but is seen on DWI b = 1000s/mm
2 (E) and
(F) is more conspicuous at DWI at b = 3000s/mm2 (Patient 12).
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changes a conserved amino acid residue, is predicted to be
damaging by both in silico prediction software PolyPhen-2
and SIFT, and is rare in control populations with a re-
ported allele frequency of 0.0014 in non-Finnish
Europeans (122/121370 in the entire series, http://exac.
broadinstitute.org/gene/ENSG00000114767).
Electroencephalography
Twenty-one patients had an EEG, six of which were ini-
tially normal. The other 15 had generalized slow activity
and one of which had short runs of periodic slow wave
complexes.
Nerve conduction studies
No systematic peripheral nerve conduction studies were
undertaken. However, four patients had been investigated
by the local clinician prior to referral to the National
Prion Clinic. One patient with wasting of the small
hand muscles and fasciculation had neurophysiological
evidence of denervation leading to an initial diagnosis
of motor neuron disease. A second patient had clinical
evidence of a length dependent sensorimotor axonal neu-
ropathy, greater in the lower limbs, assessed 1 year
before referral, while two other patients also had some
evidence of a similar sensory motor neuropathy on lim-
ited assessment.
Cerebrospinal fluid
Sixteen patients had CSF examination. The ﬂuid was acel-
lular in all. Five had a raised protein concentration
(40.41 g/l). 14-3-3 protein was sought in 14 patients and
detected in six.
Neuropathology
Nine autopsies were conducted between 2003 and 2013; the
whole brain was available in eight. We report an overview
here; a full morphological study will be reported separately.
In all cases there was variably prominent microvacuolar de-
generation in the hemispheric cortex, deep grey nuclei and
cerebellar cortex. Immunostaining for the abnormal PrP re-
vealed synaptic labelling in all grey matter areas examined
and in all but one case, there were also microplaques in all
grey matter structures (Fig. 5). Variability in the intensity of
Figure 3 MRI findings in a 47-year-old male patient with iatrogenic CJD due to growth hormone. Hyperintensity in the superior
cerebellar vermis is seen on axial FLAIR images (A), and is more conspicuous at DWI at b = 1000s/mm2 at the same level (B). (C) A more
superior axial image at DWI at b = 1000s/mm2 shows the increased vermian signal abnormality compared to the surrounding occipital cortex
(Patient 8).
Figure 4 Cumulative incidence of patients stratified by
PRNP codon 129 polymorphism. There is a highly significant
difference in the distribution of the three polymorphisms at codon
129 over time and incubation period (ANOVA, P5 107), with
each pairwise comparison of genotypes being statistically significant
in post hoc analyses (P5 0.001) as indicated in the text.
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Figure 5 Neuropathological findings in a representative iatrogenic CJD case. Sections (A–L) stained with haematoxylin and eosin.
Sections (A1–L1) immunostained for abnormal prion protein deposition with anti-PrP monoclonal antibody ICSM35. Throughout the grey matter
there is variably prominent microvacuolar degeneration and abnormal prion protein deposition in a diffuse synaptic manner and as micro-plaques.
In the anterior frontal cortex (A and B, haematoxylin and eosin) there is mild patchy microvacuolar degeneration and abnormal prion protein
deposits (A1 and B1, ICSM35) are restricted to the deep cortical layers. In the posterior frontal lobe, including motor cortex (C and D,
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(continued)
the immunoreactivity for the abnormal prion protein was
evident but detailed comparison between the cases and sep-
arately within each case was not feasible as prolonged for-
malin-ﬁxation in some cases signiﬁcantly attenuated the
immunoreactivity.
Disease-related prion protein analysis
by immunoblotting
PrPSc typing (molecular strain typing) (Collinge et al., 1996;
Hill et al., 2003) was performed with frontal cortex sam-
ples from seven patients with iatrogenic CJD where frozen
tissue was available. A representative immunoblot is shown
in Fig. 6. All seven cases showed PrPSc types that are con-
gruent with those seen in sporadic CJD. Five were 129MV
with type 3 PrPSc and two were 129MM with type 2 PrPSc
using the London classiﬁcation (Hill et al., 2003).
Discussion
This study, covering the period from 2000–14, shows that
iatrogenic CJD due to cadaver-sourced pituitary growth
hormone, a treatment that was discontinued in 1985 in
the UK, continues to occur in the UK at a frequency of
0–6 cases per annum. Incubation periods are now extraor-
dinarily long, with estimates ranging from 18–40 years, the
uncertainty based on clinical onsets and lengths of treat-
ment with potentially infected batches. In this paper we
have reviewed the clinical features, progression, imaging
abnormalities, prion protein genotype, PrPSc type by west-
ern blot and preliminary neuropathology data.
Clinical features and imaging
correlations
Typically patients with growth hormone induced iatrogenic
CJD present with gait ataxia, cerebellar dysarthria and
lower limb pain with cognitive function much less affected.
Later sleep disturbance, cognitive decline and pyramidal
signs with weakness in the lower limbs develops.
Ultimately, the patient enters an akinetic mute state typical
of all types of CJD with death at 4–32 (mean 16.0) months
after the initial presentation. There are several points of
special interest in this clinical presentation.
First, gait ataxia, with much less limb ataxia, especially in
the upper limbs, is typical of superior cerebellar vermis
damage. The MRI and pathological examination of the
cerebellum demonstrated extensive damage of the vermis
with lesser involvement of the cerebellar hemispheres con-
sistent with these clinical ﬁndings. Interestingly, in addition
to gait ataxia, two of the patients presented with abnormal
visual input imbalance characterized by unsteadiness
induced by moving stimuli (waves when paddling and look-
ing at moving water) suggesting abnormal visual vestibular
interaction partly dependent on cerebellar pathways.
Second, pain in the lower limbs was of a quality suggesting
abnormal spino-thalamic function and MRI conﬁrmed a dif-
fuse abnormality of the thalamus which, although maximal
medially, did extend laterally to the ventro-posterior compo-
nents, part of the pain and thermal pathways. Of note is the
similarity of this pain to that experienced by many patients
Figure 5 Continued
haematoxylin and eosin) there is more prominent micro-vacuolation and dense pan-cortical deposition of the abnormal prion protein (C1 and D1,
ICSM35). In the basal ganglia (E, haematoxylin and eosin; E1 ICSM35) there is very severe vacuolation and diffuse deposition of abnormal prion
protein in the neuropil of the putamen (F, haematoxylin and eosin; F1 ICSM35) and caudate nucleus. In the hippocampus (G, haematoxylin and
eosin) there is particularly prominent micro-vacuolar degeneration in the Sommer’s sector, subiculum and entorhinal cortex (H, haematoxylin and
eosin) with corresponding deposits of abnormal prion protein (G1 and H1, ICSM35). In the cerebellum there is very severe cortical atrophy in
vermis with prominent microvacuolation in the molecular layer, loss of Purkinje cells, granular cells and accompanying Bergmann gliosis (I,
haematoxylin and eosin). The cortex in the cerebellar hemisphere is much better preserved with mild degree of microvacuolar degeneration in
the molecular layer (J, haematoxylin and eosin). In both, cerebellar vermis and hemisphere there are scattered micro-plaques and diffuse, dense
synaptic labelling for abnormal prion protein. Scale bars = 4 mm in A, A1, C, C1, E, E1, I, I1, K and K1; 8 mm in G and G1; 200 mm in B, B1, D, D1,
F, F1, H, H1, J, J1, L and L1.
Figure 6 PrP immunoblot of patient brain. Proteinase K
(PK)-digested 10 % (w/v) brain homogenates from patients with
sporadic CJD or iatrogenic CJD were analysed by enhanced
chemiluminescence using anti-PrP monoclonal antibody 3F4. The
provenance of each brain sample is designated above each lane and
the type of PrPSc (London classification; Hill et al., 2003) detected in
each sample and the PRNP codon 129 genotype of the patient
(M, methionine; V, valine) is designated below. Control samples of
human PrPSc types 2 and 3 from patients with sporadic CJD (lanes 1
and 2) are compared with the PrPSc molecular strain types seen in
Patients 4, 10,11 and 12 with iatrogenic CJD (lanes 3–6).
Iatrogenic CJD due to growth hormone BRAIN 2015: 138; 3386–3399 | 3395
with variant CJD and kuru, which are also acquired prion
diseases associated with peripheral infection with prions
where thalamic involvement, especially posteriorly, occurs.
However, a contribution of the more peripheral components
of the spino-thalamic system cannot be excluded.
Third, later in the course of the disease cognitive dysfunc-
tion with prominent memory decline emerged. The exten-
sive involvement of many areas of the deep nuclei,
thalamus and cortex could explain this, but of note is the
prominent involvement of the hippocampus on MRI and
pathologically. This, together with the thalamic changes, is
an adequate explanation of the amnesia. Thalamic involve-
ment would also explain the sleep disturbance similar to
that occurring in fatal familial insomnia (FFI) and fre-
quently seen in sporadic CJD.
Finally, weakness in the lower limbs due to pyramidal in-
volvement correlated with cortical ribboning involving the
dorsal and medial motor strip demonstrated on MRI in
most patients. Such involvement of the motor cortex is rare
in other forms of prion disease. More pronounced involve-
ment of the motor cortex and parietal lobe when compared
with the anterior frontal or occipital cortex was also con-
ﬁrmed morphologically with extensive micro-vacuolar change
and intense deposition of synaptic abnormal prion protein.
Neuropathology
A detailed quantitative analysis of the pathology in the nine
autopsied cases will be the subject of a separate communi-
cation. However, a striking feature was the presence of PrP
plaques in all but one case. This latter non-plaque case
suggests that the different pathological appearances might
be caused by different prion strains. Similarly, iatrogenic
CJD due to dural grafts, a condition particularly prevalent
in Japan, may show two distinct pathologies, plaque-type
and non-plaque-type, which have been linked with differing
transmission properties in transgenic mice (Kobayashi
et al., 2014). It is possible that future studies using material
from the original batches of pituitary-derived growth hor-
mone and transgenic mice could clarify the pathogenesis of
the disease in our cases and comparison with the literature
on dural graft iatrogenic CJD.
PRNP codon 129 polymorphism
determines incubation time
A remarkable feature of iatrogenic CJD cases in the UK is
the distribution of the codon 129 polymorphism. An excess
of VV homozygotes was reported in early UK cases and
then thought to be a marker of susceptibility (Collinge
et al., 1991). MV heterozygosity was reported to confer
relative resistance to sporadic CJD (Palmer et al., 1991).
In the initial study of 27 UK patients 52% were homozy-
gous for valine and only 4% (one case) was homozygous
for methionine; the remainder were heterozygotes. This
contrasts with the French experience in 77 patients where
48% were homozygous for methionine and 22%
homozygous for valine (Brandel et al., 2003). Similar pro-
portions were also found in the few cases reported from the
USA (Brown et al., 2012). Furthermore in sporadic CJD,
kuru and variant CJD, methionine homozygosity predom-
inates. This is thought to result from the relative resistance
afforded by heterozygosity at polymorphic PrP residue 129
and from conformational selection whereby different prion
strains are preferentially propagated by prion proteins of
different primary sequence (Collinge, 1999; Collinge and
Clarke, 2007). For example the bovine spongiform enceph-
alopathy-related prion strain causing variant CJD appears
only to be compatible with methionine 129 human PrP
(Wadsworth et al., 2004).
One of the new ﬁndings of our study of UK patients is
that there has been a change in the distribution of the 129
polymorphism in the past 12 years. The VV genotype has
now greatly decreased and MM genotype increased while
the frequency of heterozygotes has remained relatively con-
stant. There are similarities and differences from the studies
of kuru (Cervenakova et al., 1999; Collinge et al., 2006;
Mead et al., 2009b). In kuru both homozygous genotypes
predominated in young cases with presumably a shorter
incubation time, but in later and older cases heterozygotes
occurred more frequently.
A possible explanation for these superﬁcially contradict-
ory distributions of codon 129 in different outbreaks could
be the compatibility of host genotype and strain of the
infecting prion, in keeping with the conformational selec-
tion model of prion transmission (Collinge, 1999; Collinge
and Clarke, 2007). This model suggests that transmission is
facilitated, with shorter incubation times, if the host prion
protein can readily adopt the preferred conformation asso-
ciated with the strain of the infecting prion. In the case of
the UK, it is likely that one particular preparation (Hartree
modiﬁed Wilhelmi preparation) was responsible for the
outbreak as all patients to date received this preparation.
Swerdlow et al. (2003) estimated that 400000 pitui-
taries were harvested for growth hormone production,
but even this may be an underestimate. Attempts were
made to exclude patients who had neurological diseases
but protocols for harvesting were not strictly monitored
(Swerdlow et al., 2003). It is likely that some of these pi-
tuitary glands were sourced from cases with CJD; in the
1970s, the time when the majority of pituitary sourced
growth hormone was obtained, it is estimated from UK
mortality data that 1 in 7000 deaths would have been
due to sporadic CJD. Two-thirds of cases of sporadic
CJD worldwide are of the 129MM genotype and therefore
it is not surprising that most cases of iatrogenic CJD out-
side the UK were of this genotype. However, in the present
series, the pattern was different with the early patients,
which were predominantly of the VV genotype. As only
24% of cases of sporadic CJD are 129VV the question
arises as to why the UK patients differ from the rest of the
world in this regard.
One possibility is that the screening of donors was more
successful than suggested above and by chance only one or
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two cases of sporadic CJD were the source of the growth
hormone and these had an atypical phenotype that occured
more frequently in VV or MV cases. Alternatively many
donors were included, however, a single VV or MV case
had a particularly high titre of infective material in the
pituitary. The profound inﬂuence of codon 129 in control-
ling human prion transmission barriers has been extensively
modelled in transgenic mice expressing human PrP on a
mouse PrP null background (Wadsworth et al., 2010).
These studies have shown that transmission barriers to in-
fection with classical CJD prions are asymmetric, depend-
ent upon the codon 129 genotype of the prion source and
the recipient (Wadsworth et al., 2010). Whereas, transgenic
mice expressing human PrP 129 valine are highly suscep-
tible to classical CJD prions regardless of the PrPSc type or
codon 129 genotype of the inoculum (Collinge et al., 1995,
1996; Telling et al., 1995; Hill et al., 1997; Korth et al.,
2003; Kobayashi et al., 2007; Wadsworth et al., 2008b),
the absence of a transmission barrier to classical CJD
prions is not uniformly observed in mice expressing
human PrP 129 methionine in the absence of mouse PrP.
Here, mismatch at residue 129 between the inoculum and
host can signiﬁcantly affect transmission. Thus while there
appears to be no barrier to transmission of classical CJD
prions from codon 129 methionine homozygous patients
(Asante et al., 2002; Korth et al., 2003; Beringue et al.,
2008; Kong et al., 2008), transmission of classical CJD
prions from valine homozygous patients is often associated
with more prolonged and variable incubation periods and
reduced attack rates (Asante et al., 2002; Korth et al.,
2003; Kobayashi et al., 2007, 2015). In the case of classical
CJD prions from codon 129 heterozygous patients the
transmission efﬁciency in transgenic mice expressing
human PrP 129 methionine varies dependent upon PrPSc
type and whether prions are propagated on human PrP
with methionine or valine at residue 129 (Asante et al.,
2002; Korth et al., 2003; Bishop et al., 2010; Kobayashi
et al., 2015). These data provide an experimental back-
ground with which to interpret the temporal distribution
of codon 129 genotypes within the cohort of iatrogenic
CJD patients in the UK and suggest that the infecting
prion contamination of growth hormone was from a VV
or MV individual.
Finally, the signiﬁcance of the polymorphism in RRP9
found on exome sequencing is unclear. The sample is
small and the ﬁnding requires replication in an independent
cohort. Any association could be related to either the initial
condition for which the patients were treated or iatrogenic
disease or both.
Mismatch of incubation period and
rapidity of symptomatic progression
A further seemingly paradoxical observation is that those
recent clinical cases with particularly long incubation times
have had the shortest clinical durations once symptomatic.
Rates of clinical decline in our series of iatrogenic CJD
have been most in keeping with observations of sporadic
CJD with the MM genotype being more rapid than MV
(Pocchiari et al., 2004). A plausible explanation for these
observations is that the generation of a host prion strain
compatible with host genotype occurs in the periphery
during the prolonged incubation time; however, following
CNS invasion the rapidity of disease progression [which is
thought to be determined by the rates of production of
toxic PrP species (designated PrPL for lethal); Hill et al.,
2000; Collinge and Clarke, 2007; Sandberg et al., 2011,
2014] is more rapid in MM versus MV individuals owing
to higher levels of homotypic substrate PrP available for
conversion.
Conclusion
This study is the ﬁrst to clearly deﬁne the clinical, imaging
and neuro-pathological characteristics of patients with iat-
rogenic CJD due to cadaver-sourced growth hormone. It
demonstrates that cases continue to occur at a low but
steady rate in the UK and that the incubation period can
be up to four decades. We have shown that all three
common genotypes at PRNP are susceptible albeit with
markedly different incubation periods, a phenomenon also
seen in kuru. Whether similar susceptibility, with differing
mean incubation times, will be seen in the UK related to the
transmission of bovine spongiform encephalopathy prions
remains to be seen. Further, we have demonstrated a dis-
sociation between the incubation period and the rapidity of
decline once a person develops symptoms.
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